Lingran Du
Impact in
- Pharmaceutical Science top 5%
- Advancements in Transdermal Drug Delivery
- Advanced Drug Delivery Systems
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Advanced Drug Delivery Systems 3
- Advancements in Transdermal Drug Delivery 2
-
- Nanoparticle-Based Drug Delivery 2
- Co-authors
- Jijun Fu (10 shared papers)Yi Zhou (7 shared papers)Xiyong Yu (6 shared papers)Yugang Huang (9 shared papers)He Wang (4 shared papers)Minyan Wei (4 shared papers)Liang Gu (1 shared paper)Jiayi Guo (1 shared paper)
- Journals
- International Journal of Pharmaceutics (3 papers)Acta Pharmaceutica Sinica B (2 papers)Journal of Nanobiotechnology (2 papers)Journal of Hematology & Oncology (1 paper)International Journal of Biological Macromolecules (1 paper)
- Partner nations
- ChinaMacaoUnited States
In The Last Decade
Lingran Du
22 papers receiving 490 citations
Peers
Comparison fields: 5 of 80
- Pharmaceutical Science 77
- Biomaterials 112
- Molecular Medicine 19
- Cancer Research 52
- Biomedical Engineering 147
Countries citing papers authored by Lingran Du
This map shows the geographic impact of Lingran Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingran Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingran Du more than expected).
Fields of papers citing papers by Lingran Du
This network shows the impact of papers produced by Lingran Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingran Du. The network helps show where Lingran Du may publish in the future.
Co-authors
The 25 scholars most cited alongside Lingran Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 99 | |
| 2 | 2019 | 64 | |
| 3 | 2020 | 55 | |
| 4 | 2015 | 53 | |
| 5 | 2014 | 42 | |
| 6 | 2018 | 40 | |
| 7 | 2019 | 27 | |
| 8 | 2007 | 27 | |
| 9 | 2014 | 15 | |
| 10 | 2021 | 13 | |
| 11 | 2020 | 13 | |
| 12 | 2021 | 12 | |
| 13 | 2013 | 8 | |
| 14 | 2020 | 7 | |
| 15 | 2023 | 5 | |
| 16 | 2023 | 3 | |
| 17 | 2024 | 3 | |
| 18 | 2022 | 2 | |
| 19 | 2023 | 2 | |
| 20 | 2025 | 2 |
About Lingran Du
Lingran Du is a scholar working on Pharmaceutical Science, Biomaterials, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Polymers and Plastics, having authored 22 papers that have together received 494 indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (3 papers), Advanced Drug Delivery Systems (3 papers), Advanced biosensing and bioanalysis techniques (3 papers), Advancements in Transdermal Drug Delivery (2 papers), Intracranial Aneurysms: Treatment and Complications (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Nanoparticle-Based Drug Delivery (2 papers) and Nanoplatforms for cancer theranostics (2 papers). The work is most often cited by research in Pharmaceutical Science (77 citations), Biomaterials (112 citations), Molecular Medicine (19 citations), Cancer Research (52 citations) and Biomedical Engineering (147 citations). Lingran Du has collaborated with scholars based in China, Macao and United States. Frequent co-authors include Jijun Fu, Yi Zhou, Xiyong Yu, Yugang Huang, He Wang, Minyan Wei, Liang Gu, Jiayi Guo, Xiaoqin Zhou and Ying‐Hong Feng. Their work appears in journals such as International Journal of Pharmaceutics, Acta Pharmaceutica Sinica B, Journal of Nanobiotechnology, Journal of Hematology & Oncology and International Journal of Biological Macromolecules.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.